Clinical Trial Update: Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Clinical trial update for a Phase 2 study comparing sequencing Sacituzumab Govitecan (SG) versus Trastuzumab Deruxtecan (T-DXd) in HER2-low/TROP2-high metastati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Sacituzumab Govitecan (Trodelvy) (sacituzumab govitecan)
• Trastuzumab Deruxtecan (Enhertu) (trastuzumab deruxtecan)

Snippet

Sponsor: Fudan University | Conditions: Metastatic Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING